GLAD - Prevention of postpsychotic depression with Lamotrigine
Who Can Participate?
- Males or females between the ages of 18-40 diagnosed with schizophrenia in the past 5 years
What is involved?
- Patients will receive study medication in addition to their current antipsychotic medication.
- Patients start as inpatients and then move to outpatient visits.
- 21 study visits over 52 weeks, with each visit not lasting longer than 1.5 hours
What will I be compensated?
- Free study related medication and psychiatric treatment
- $25 per completed study visit
CAMP - Clinical management of metabolic problems in patients with schizophrenia: Switching to aripiprazole versus continued treatment with olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal)
Who Can Participate?
- Males or females between the ages of 18-65 diagnosed with schizophrenia or schizoaffective disorder
- Currently taking Risperdal, Seroquel or Zyprexa who may be considering a medication change because of weight gain, high cholesterol, or other health problems
What is involved?
- Patients will continue on their current medication or be switched to aripiprazole (Abilify) and receive a individual behavioral plan to help them lose weight.
- This is an outpatient study
- 11 study visits over 6 months
What will I be compensated?
- Free study related medication and treatment
- Free pedometer and scale
- Up to $25 per completed study visit
CONNECT - A 24-week multicenter, double-blind, randomized, parallel-group, dose ranging study of the efficacy and safety of oral doses of AVE 1625 5, 10, and 30 mg and placebo on top of an established treatment regimen of either olanzapine, risperidone/paliperidone, quetiapine or aripiprazole monotherapy in the treatment of cognitive impairment in schizophrenia
Who Can Participate?
- Males or females between the ages of 18-65 diagnosed with schizophrenia at or before the age of 35
- Currently taking Zyprexa, Risperdal, Seroquel, Invega or Abilify.
What is involved?
- Patients will receive either the study drug or a placebo in addition to their current antipsychotic medication
- This is an outpatient study
- 18 visits over 33 weeks
What will I be compensated?
- Free study related medication and psychiatric treatment
- Patients will receive $50 for completed visits 1, 2, 7, 11, and 15 and $25 for all other completed visits. They will be paid an additional $25 for participating in the optional genetics component of the study.
OTS - A randomized, double-blind, placebo-controlled study to compare the effects of two weeks of daily administration of oxytocin vs. placebo on social cognition, paranoia and other psychotic symptoms, and social competence in patients with schizophrenia
Who Can Participate?
- Males or females between the ages of 18-55 diagnosed with schizophrenia, paranoid or undifferentiated type, for at least 1 year
What is involved?
- Participants will be inpatient for 2-3 weeks
- Participants will receive either oxytocin or placebo intranasal spray in addition to their current antipsychotic for 2 weeks
- Participants will have a screening visit and study visits at baseline and on treatment days 3, 7, and 14. Patients will be contacted by phone 4 to 7 days after the treatment phase to assess for physical or psychological symptoms
- Study visits will last approximately 2 hours
What will I be compensated?
- Free study related medication and psychiatric treatment
- Patients will be compensated for their time and effort
|
